INS and type 2 diabetes mellitus: Evidence from epidemiological studies indicates that men with T2DM using insulin sensitizers, such as metformin and TZDs, lost significantly less SMM (−1.1 vs. −2.9%) or ASM (−1.8 vs. 4.4%) than those treated without insulin sensitizers [58].